Role of Chemoradiotherapy in Oesophageal Cancer — Adjuvant and Neoadjuvant Therapy

Despite low postoperative mortality rates, the long-term outcomes from surgical-based treatment for oesophageal cancer remain poor. Chemoradiotherapy (CRT), either given before surgical resection as neoadjuvant therapy or after resection as adjuvant therapy, has been postulated to improve these outcomes. This systematic review examines the evidence for these approaches. The evidence for postoperative radiotherapy is limited and conclusions are difficult, but it may have a role in patients at high risk of local relapse (positive margins). The addition of chemotherapy is recommended when possible. Patient selection is important due to the associated toxicities. The evidence for neoadjuvant treatment is stronger and based on the current evidence neoadjuvant CRT can be recommended as a treatment approach in T2–T4, N1–3 oesophageal cancer for both adenocarcinoma and squamous cell carcinoma, but further work is needed to establish its superiority over neoadjuvant chemotherapy alone, particularly for adenocarcinoma. We recommend that further studies divide the two histologies and they should be treated as two separate diseases.     

内镜下切除术治疗成人重复胃畸形的疗效

目的 探讨内镜下切除的胃重复畸形的病例特征及其预后。方法 选择2017年1月至2021年1月在复旦大学附属中山医院进行内镜切除治疗且病理证实为胃重复畸形的患者9例,回顾性收集其临床病理资料,包括一般资料、内镜下病灶表现、术后病理、住院天数、术后并发症、随访情况等。结果 共纳入9例胃重复畸形患者,女性3例,男性 6例;2例患者病灶位于胃上1/3,2例位于胃中1/3,5例位于胃下1/3。8例患者内镜下表现为黏膜下肿瘤,仅1例表现为息肉样隆起。住院天数为2（1.5, 4）d,无围手术期不良事件,随访时间46（26, 51）个月。术后随访病灶无残留、无复发。结论 内镜下切除对于符合指征的胃重复畸形的治疗安全可行,临床可尝试推广。     

Endoscopic full-thickness resection,indication, methods and perspectives

Minimally invasive surgery has emerged as the dominant theme of modern surgery, in which endoscopic surgery plays a key role. The technique of endoscopic surgery has evolved continuously with extensive research, improving the treatment modalities as well as expanding the indications for its use. As an active perforation endoscopic technique, endoscopic full-thickness resection (EFTR) is mainly used in the treatment of submucosal tumors (SMTs) of the gastrointestinal tract. With decades of evolution, EFTR has gradually developed into a mature endoscopic operation. Based on clinical experience and current research, indications, techniques, clinical outcomes and future perspectives for EFTR are discussed in this paper. We performed a bibliometric study on EFTR literature and showed robust data through a brief meta-analysis on the topic.